• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

PCSK9i and atherosclerotic plaque regression assessed by coronary computed tomography angiography: a meta-analysis.

作者信息

Sagris Marios, de Isla Leopoldo Pérez, Korosoglou Grigorios

机构信息

School of Medicine, 'Hippokration' General Hospital, National and Kapodistrian University of Athens, Vasilissis Sofias 114, 11528, Athens, Greece.

Department of Cardiology, "Tzaneio" General Hospital of Piraeus, Piraeus, Greece.

出版信息

Clin Res Cardiol. 2025 May 19. doi: 10.1007/s00392-025-02672-x.

DOI:10.1007/s00392-025-02672-x
PMID:40387889
Abstract
摘要

相似文献

1
PCSK9i and atherosclerotic plaque regression assessed by coronary computed tomography angiography: a meta-analysis.通过冠状动脉计算机断层扫描血管造影评估的前蛋白转化酶枯草溶菌素9抑制剂（PCSK9i）与动脉粥样硬化斑块消退：一项荟萃分析
Clin Res Cardiol. 2025 May 19. doi: 10.1007/s00392-025-02672-x.
2
Clinical impact of PCSK9 inhibitor on stabilization and regression of lipid-rich coronary plaques: a near-infrared spectroscopy study.前蛋白转化酶枯草溶菌素9（PCSK9）抑制剂对富含脂质的冠状动脉斑块稳定和消退的临床影响：一项近红外光谱研究
Eur Heart J Cardiovasc Imaging. 2022 Jan 24;23(2):217-228. doi: 10.1093/ehjci/jeab034.
3
Machine Learning Framework to Identify Individuals at Risk of Rapid Progression of Coronary Atherosclerosis: From the PARADIGM Registry.机器学习框架识别冠状动脉粥样硬化快速进展风险个体：来自 PARADIGM 登记研究。
J Am Heart Assoc. 2020 Mar 3;9(5):e013958. doi: 10.1161/JAHA.119.013958. Epub 2020 Feb 22.
4
Diffuse coronary artery disease among other atherosclerotic plaque characteristics by coronary computed tomography angiography for predicting coronary vessel-specific ischemia by fractional flow reserve.通过冠状动脉计算机断层扫描血管造影术评估弥漫性冠状动脉疾病及其他动脉粥样硬化斑块特征，以通过血流储备分数预测冠状动脉血管特异性缺血。
Atherosclerosis. 2017 Mar;258:145-151. doi: 10.1016/j.atherosclerosis.2017.01.018. Epub 2017 Jan 16.
5
Noninvasive Imaging of Atherosclerotic Plaque Progression: Status of Coronary Computed Tomography Angiography.动脉粥样硬化斑块进展的无创成像：冠状动脉计算机断层扫描血管造影的现状
Circ Cardiovasc Imaging. 2015 Jul;8(7):e003316. doi: 10.1161/CIRCIMAGING.115.003316.
6
Aggravating effect of abnormal low-density protein cholesterol level on coronary atherosclerotic plaque in type 2 diabetes mellitus patients assessed by coronary computed tomography angiography.冠状动脉计算机断层血管摄影评估 2 型糖尿病患者异常低密脂蛋白胆固醇水平对冠状动脉粥样硬化斑块的恶化作用。
Cardiovasc Diabetol. 2024 Jul 4;23(1):234. doi: 10.1186/s12933-024-02304-0.
7
Clinical and Coronary Plaque Predictors of Atherosclerotic Nonresponse to Statin Therapy.他汀类药物治疗动脉粥样硬化无反应的临床及冠状动脉斑块预测因素
JACC Cardiovasc Imaging. 2023 Apr;16(4):495-504. doi: 10.1016/j.jcmg.2022.10.017. Epub 2022 Dec 14.
8
Clinical Relevance of Coronary Computed Tomography Angiography Beyond Coronary Artery Stenosis.冠状动脉计算机断层扫描血管造影的临床意义不仅仅在于冠状动脉狭窄。
Rofo. 2021 Oct;193(10):1162-1170. doi: 10.1055/a-1395-7905. Epub 2021 Mar 26.
9
Comparative differences in the atherosclerotic disease burden between the epicardial coronary arteries: quantitative plaque analysis on coronary computed tomography angiography.比较心外膜冠状动脉粥样硬化病变负担的差异：冠状动脉 CT 血管造影的定量斑块分析。
Eur Heart J Cardiovasc Imaging. 2021 Feb 22;22(3):322-330. doi: 10.1093/ehjci/jeaa275.
10
Association of Lipoprotein (a) With Coronary-Computed Tomography Angiography-Assessed High-Risk Coronary Disease Attributes and Cardiovascular Outcomes.载脂蛋白(a)与冠状动脉计算机断层血管造影评估的高危冠状动脉疾病特征及心血管结局的关系。
Circ Cardiovasc Imaging. 2022 Dec;15(12):e014611. doi: 10.1161/CIRCIMAGING.122.014611. Epub 2022 Dec 12.

本文引用的文献

1
Evolocumab attenuate pericoronary adipose tissue density via reduction of lipoprotein(a) in type 2 diabetes mellitus: a serial follow-up CCTA study.依洛尤单抗通过降低 2 型糖尿病脂蛋白（a）减轻冠状动脉脂肪组织密度：一项连续随访的 CCTA 研究。
Cardiovasc Diabetol. 2023 May 22;22(1):121. doi: 10.1186/s12933-023-01857-w.
2
Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients with Familial Hypercholesterolemia: The ARCHITECT Study.依洛尤单抗与家族性高胆固醇血症无症状患者的冠状动脉粥样硬化：ARCHITECT 研究。
Circulation. 2023 May 9;147(19):1436-1443. doi: 10.1161/CIRCULATIONAHA.122.062557. Epub 2023 Apr 3.
3
Serial Changes in Coronary Plaque Formation Using CT Angiography in Patients Undergoing PCSK9-Inhibitor Therapy With 1-year Follow-up.
在接受 PCSK9 抑制剂治疗的患者中，使用 CT 血管造影术进行 1 年随访，观察冠状动脉斑块形成的连续变化。
J Thorac Imaging. 2022 Sep 1;37(5):285-291. doi: 10.1097/RTI.0000000000000666. Epub 2022 Jul 8.
4
Effect of Alirocumab on Coronary Calcification in Patients With Coronary Artery Disease.阿利西尤单抗对冠状动脉疾病患者冠状动脉钙化的影响。
Front Cardiovasc Med. 2022 May 6;9:907662. doi: 10.3389/fcvm.2022.907662. eCollection 2022.
5
The annual rate of coronary artery calcification with combination therapy with a PCSK9 inhibitor and a statin is lower than that with statin monotherapy.使用前蛋白转化酶枯草溶菌素9（PCSK9）抑制剂与他汀类药物联合治疗时的冠状动脉钙化年发生率低于单独使用他汀类药物治疗时的发生率。
NPJ Aging Mech Dis. 2018 Jun 22;4:7. doi: 10.1038/s41514-018-0026-2. eCollection 2018.